16888080

Source:http://linkedlifedata.com/resource/pubmed/id/16888080

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0024305, umls-concept:C0034656, umls-concept:C0087111, umls-concept:C0205265, umls-concept:C0282461, umls-concept:C0580822, umls-concept:C1274040, umls-concept:C1328050, umls-concept:C1512888, umls-concept:C1547300, umls-concept:C1548760, umls-concept:C1550594, umls-concept:C1555582, umls-concept:C1705294
pubmed:issue	10
pubmed:dateCreated	2006-9-28
pubmed:abstractText	Sequential high dose (SHiDo) chemotherapy with stem cell support has been shown to prolong the event-free survival in patients with diffuse large B-cell lymphoma.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Prednisone, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	0923-7534
pubmed:author	pubmed-author:AulitzkyW EWE, pubmed-author:BeckJJ, pubmed-author:BetticherD CDC, pubmed-author:CernyTT, pubmed-author:CinaSS, pubmed-author:CogliattiS BSB, pubmed-author:DyerM J SMJ, pubmed-author:KaiserUU, pubmed-author:KaufmannMM, pubmed-author:KovascovicsTT, pubmed-author:LinchD CDC, pubmed-author:MaibachRR, pubmed-author:MartinelliGG, pubmed-author:RadfordJ AJA, pubmed-author:von RohrAA
pubmed:issnType	Print
pubmed:volume	17
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1546-52
pubmed:meshHeading	pubmed-meshheading:16888080-Adolescent, pubmed-meshheading:16888080-Adult, pubmed-meshheading:16888080-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16888080-Cyclophosphamide, pubmed-meshheading:16888080-Disease-Free Survival, pubmed-meshheading:16888080-Dose-Response Relationship, Drug, pubmed-meshheading:16888080-Doxorubicin, pubmed-meshheading:16888080-Drug Administration Schedule, pubmed-meshheading:16888080-Feasibility Studies, pubmed-meshheading:16888080-Female, pubmed-meshheading:16888080-Humans, pubmed-meshheading:16888080-Lymphoma, Non-Hodgkin, pubmed-meshheading:16888080-Male, pubmed-meshheading:16888080-Middle Aged, pubmed-meshheading:16888080-Multivariate Analysis, pubmed-meshheading:16888080-Neoadjuvant Therapy, pubmed-meshheading:16888080-Prednisone, pubmed-meshheading:16888080-Recurrence, pubmed-meshheading:16888080-Salvage Therapy, pubmed-meshheading:16888080-Survival Analysis, pubmed-meshheading:16888080-Vincristine
pubmed:year	2006
pubmed:articleTitle	Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).
pubmed:affiliation	SAKK (Swiss Group for Clinical Cancer Research), Bern, Switzerland. betticherd@hopcantfr.ch
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III